Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and New

Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor College of Medicine, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer. He considers the potential for enhancements in treatment, especially in Bacillus Calmette-Guerin (BCG) unresponsive patients.